Cargando…

Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm

Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojtukiewicz, Marek Z., Skalij, Piotr, Tokajuk, Piotr, Politynska, Barbara, Wojtukiewicz, Anna M., Tucker, Stephanie C., Honn, Kenneth V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281117/
https://www.ncbi.nlm.nih.gov/pubmed/32370207
http://dx.doi.org/10.3390/cancers12051144
_version_ 1783543847575355392
author Wojtukiewicz, Marek Z.
Skalij, Piotr
Tokajuk, Piotr
Politynska, Barbara
Wojtukiewicz, Anna M.
Tucker, Stephanie C.
Honn, Kenneth V.
author_facet Wojtukiewicz, Marek Z.
Skalij, Piotr
Tokajuk, Piotr
Politynska, Barbara
Wojtukiewicz, Anna M.
Tucker, Stephanie C.
Honn, Kenneth V.
author_sort Wojtukiewicz, Marek Z.
collection PubMed
description Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its prevention. Direct oral anticoagulants (DOACs) are a new option for anticoagulation therapy. Recently published results of large randomized clinical trials have confirmed that DOAC may be a reasonable alternative to LMWH in cancer patients. The following review summarizes the current evidence on the safety and efficacy of DOAC in the treatment and prevention of cancer-related thrombosis. It also draws attention to the limitations of this group of drugs, knowledge of which will facilitate the selection of optimal therapy.
format Online
Article
Text
id pubmed-7281117
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72811172020-06-15 Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm Wojtukiewicz, Marek Z. Skalij, Piotr Tokajuk, Piotr Politynska, Barbara Wojtukiewicz, Anna M. Tucker, Stephanie C. Honn, Kenneth V. Cancers (Basel) Review Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its prevention. Direct oral anticoagulants (DOACs) are a new option for anticoagulation therapy. Recently published results of large randomized clinical trials have confirmed that DOAC may be a reasonable alternative to LMWH in cancer patients. The following review summarizes the current evidence on the safety and efficacy of DOAC in the treatment and prevention of cancer-related thrombosis. It also draws attention to the limitations of this group of drugs, knowledge of which will facilitate the selection of optimal therapy. MDPI 2020-05-02 /pmc/articles/PMC7281117/ /pubmed/32370207 http://dx.doi.org/10.3390/cancers12051144 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wojtukiewicz, Marek Z.
Skalij, Piotr
Tokajuk, Piotr
Politynska, Barbara
Wojtukiewicz, Anna M.
Tucker, Stephanie C.
Honn, Kenneth V.
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_full Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_fullStr Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_full_unstemmed Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_short Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
title_sort direct oral anticoagulants in cancer patients. time for a change in paradigm
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281117/
https://www.ncbi.nlm.nih.gov/pubmed/32370207
http://dx.doi.org/10.3390/cancers12051144
work_keys_str_mv AT wojtukiewiczmarekz directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT skalijpiotr directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT tokajukpiotr directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT politynskabarbara directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT wojtukiewiczannam directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT tuckerstephaniec directoralanticoagulantsincancerpatientstimeforachangeinparadigm
AT honnkennethv directoralanticoagulantsincancerpatientstimeforachangeinparadigm